SCHEMBL10026580

SCHEMBL10026580

COc1c(-c2ccc(O)c(O)c2)oc2cc(O)cc(C)c2c1=O

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLH Q9Y253 5/20 0.82
KDM4E B2RXH2 2/20 0.82
POLB P06746 2/20 0.82
APEX1 P27695 2/20 0.82
RECQL P46063 2/20 0.82
MEN1 O00255 1/20 0.82
MMP1 P03956 1/20 0.82
GAA P10253 1/20 0.82
MAPT P10636 1/20 0.82
HTT P42858 1/20 0.82
BLM P54132 1/20 0.82
KMT2A Q03164 1/20 0.82
HSD17B10 Q99714 1/20 0.82
NOX4 Q9NPH5 2/20 0.72
PLG P00747 1/20 0.72
XDH P47989 1/20 0.70
TUBB4A P04350 1/20 0.67
TUBB P07437 1/20 0.67
TUBA3C P0DPH7 1/20 0.67
TUBA1B P68363 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
3-O-Methylquercetin SCHEMBL380558 0.90 POLH (1.00) POLHKDM4EPOLBAPEX1RECQL
3-O-Methylquercetin SCHEMBL29897544 0.90 POLH (1.00) POLHKDM4EPOLBAPEX1RECQL
SCHEMBL31304741 0.88 POLB (0.82) POLHKDM4EPOLBAPEX1RECQL
SCHEMBL30284949 0.88 POLB (0.82) POLHKDM4EPOLBAPEX1RECQL
SCHEMBL11149169 0.88 POLB (0.82) POLHKDM4EPOLBAPEX1RECQL
SCHEMBL13780248 0.85 POLH (0.82) POLHKDM4EPOLBAPEX1RECQL
SCHEMBL4227938 0.85 POLH (0.60) POLHKDM4EPOLBAPEX1RECQL
SCHEMBL4230543 0.85 POLH (0.75) POLHKDM4EPOLBAPEX1RECQL
SCHEMBL13856525 0.85 MEN1 (0.78) POLHKDM4EPOLBAPEX1RECQL
SCHEMBL828941 0.84 PLG (1.00) POLHKDM4EPOLBAPEX1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170049793-A1 MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY THE GENERAL HOSPITAL CORPORATION (US) 2017-02-23 US disclosed
US-20140187510-A1 MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY THE GENERAL HOSPITAL CORPORATION (US) 2014-07-03 US disclosed
US-20120046242-A1 MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046242-A1 MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY WNT1, CTNNB1, WNT3A POLH 2935/4885KDM4E 4001/4885POLB 2990/4885
US-20140187510-A1 MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY WNT1, CTNNB1, WNT3A POLH 2935/4885KDM4E 4001/4885POLB 2990/4885
US-20170049793-A1 MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY WNT1, CTNNB1, WNT3A POLH 2935/4885KDM4E 4001/4885POLB 2990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.